Exploring decisions surrounding the optimisation of Androgen Deprivation Therapy (ADT) use for appropriate prostate cancer (PCa) patients in the NHS in light of COVID-19
Information intended for UK healthcare professionals only. This promotional supplement has been commissioned and funded by Ipsen UK Ltd and developed in partnership with Guidelines in Practice.
View DECAPEPTYL® SR (triptorelin) 3mg, DECAPEPTYL® SR (triptorelin) 11.25mg and DECAPEPTYL® SR (triptorelin) 22.5mg prescribing information and adverse event reporting information here
TRI-UK-004677
Date of preparation: October 2021
Best practice in the management of advanced breast cancer: the role of CDK4/6 inhibitors versus chemotherapy – A Pfizer sponsored roundtable discussion
This content has been produced in line with the IBRANCE®▼ (palbociclib) Summary of Product Characteristics for Great Britain. This piece is intended for GB healthcare professionals only. This roundtable discussion has been commissioned and funded by Pfizer Ltd and developed in partnership with Guidelines in Practice.
Prescribing information and adverse event reporting information for IBRANCE® (palbociclib) for Great Britain can be accessed here
PP-IBR-GBR-3703 | Date of preparation: October 2021
The unrecognised epidemic of vitamin D deficiency in Black, Asian and Minority Ethnic (BAME) groups: a consensus document
Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by STADA incorporating Thornton & Ross, who provided the content.
TR-088d Date of preparation: August 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd
Improving outcomes in the management of patients with chronic coronary syndrome and stable anginal chest pain for the acute and general physician
Information intended for UK healthcare professionals only.
This promotional supplement has been commissioned and funded by A. Menarini Farmaceutica Internazionale SRL and developed in partnership with Guidelines in Practice.
View Ranexa (ranolazine) prescribing information and adverse event reporting information here
PP-RA-UK-0627
Date of preparation: July 2021
Methofill® (methotrexate) SelfDose for the treatment of adult patients with rheumatoid arthritis, Crohn’s disease, and psoriasis*
Intended for UK Healthcare professionals only.
This promotional supplement has been commissioned and funded by Accord-UK Ltd and developed in partnership with Guidelines in Practice.
Click here for Methofill® (methotrexate) prescribing information and adverse event reporting
For full indications, please consult the summary of product characteristics.
UK-03037 | Date of preparation: May 2021
Prostap® DCS (leuprorelin acetate)—a 3-monthly gonadotrophin-releasing hormone (GnRH) agonist treatment for breast cancer
Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Takeda UK Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
C-APROM/UK/PRS/0152
Date of preparation: April 2021
Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK
This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
Showcasing local best practice in diabetes
This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care:
Identification and management of patients with malnutrition
This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.